Pharmaceutical composition for preventing or treating cancer or inflammatory disease
A pharmaceutical composition using extracellular vesicles from Akkermansia muciniphila strain EB-AMDK39 targets cancer cells effectively, reducing tumor growth and metastasis with enhanced immune activation, addressing the limitations of current cancer treatments.
Patent Information
- Application Number
- JP2024532796
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-07-18
- Filing Date
- 2022-12-16
- Publication Date
- 2024-11-15
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current cancer treatments, such as chemotherapy and radiation therapy, have severe side effects on normal cells and often lead to drug resistance, while combination therapies with immune checkpoint inhibitors and probiotics are under-researched for various cancers.
A pharmaceutical composition containing extracellular vesicles derived from Akkermansia sp., particularly the Akkermansia muciniphila strain EB-AMDK39, which can be administered alone or in combination with immuno-anticancer drugs to target cancer cells, reducing side effects and enhancing efficacy.
The composition effectively reduces tumor size, inhibits metastasis and angiogenesis, and activates the immune system, offering better anticancer effects than single-drug administration, with reduced side effects and improved immune response.
Smart Images

Figure 2024542749000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to a pharmaceutical composition for preventing or treating cancer or an inflammatory disease, and more particularly to a pharmaceutical composition for preventing or treating cancer or an inflammatory disease, comprising extracellular vesicles (EVs) derived from Akkermansia sp. as an active ingredient. [Background technology]
[0002] Cancer is the product of uncontrolled and unregulated cell proliferation caused by an excess of abnormal cells. Malignant tumors have the property of growing rapidly by leaving the primary site and invading other tissues, thus threatening life.
[0003] In order to treat cancer, various therapeutic approaches have been attempted, such as chemotherapy using various anticancer drugs, radiation therapy, and antibody therapy targeting specific in vivo molecules related to cancer. However, chemotherapy and radiation therapy have severe side effects because they also affect normal cells, and cancer cells acquire resistance to the anticancer drugs, so treatment often fails or recurs.
[0004] Recent research reports have shown that extracellular vesicles play an important role in processes such as intercellular signaling and waste management, and interest in their clinical application has been growing recently. By utilizing the characteristics of specific extracellular vesicles and the cell membrane of target cells, it is expected that it will be possible to develop therapeutic drugs that can prevent side effects on other normal cells and specifically treat only diseased cells, including cancer cells.
[0005] Meanwhile, the importance of research into the combined therapy of probiotics, which have beneficial effects on the body such as strengthening the immune system, and immune checkpoint inhibitors has been emphasized in the field of pharmabiotics. However, research into this topic for various cancers has been very limited. Summary of the Invention [Problem to be solved by the invention]
[0006] The present invention is intended to solve the above-mentioned technical problems, and an object of the present invention is to provide a pharmaceutical composition for preventing or treating cancer or inflammatory diseases, comprising extracellular vesicles derived from pharmacobiotics.
[0007] Another object of the present invention is to provide a health functional food for preventing or improving cancer.
[0008] It is yet another object of the present invention to provide a veterinary composition or feed additive for the prevention or treatment of cancer or inflammatory diseases.
[0009] Yet another object of the present invention is to provide a method for treating cancer in a patient by activating the patient's immune system with pharmacobiotic-derived extracellular vesicles. [Means for solving the problem]
[0010] In order to achieve the above object, one aspect of the present invention is to The present invention relates to a pharmaceutical composition for preventing or treating cancer or inflammatory diseases, which contains extracellular vesicles (EVs) derived from Akkermansia sp. as an active ingredient.
[0011] The Akkermansia strain may be an Akkermansia muciniphilla strain, preferably an Akkermansia muciniphilla EB-AMDK39 strain (KCTC13765BP).
[0012] The pharmaceutical composition for preventing or treating cancer or inflammatory disease of the present invention may further contain a cancer therapeutic agent such as a chemical anticancer agent or an immune anticancer agent. The immune anticancer agent may be selected from the group consisting of anti-PD1, anti-PDL1, anti-CTLA, anti-Tim3, and anti-LAG3. The extracellular vesicles (EVs) derived from Akkermansia sp. and the chemical anticancer agent or the immune anticancer agent may be administered simultaneously in one dosage form, or simultaneously or sequentially in separate dosage forms.
[0013] Another aspect of the present invention relates to a health functional food for preventing or improving cancer, which contains extracellular vesicles (EVs) derived from Akkermansia sp. as an active ingredient.
[0014] Yet another aspect of the present invention relates to a method for treating cancer, comprising administering to a subject a therapeutically effective amount of extracellular vesicles (EVs) derived from an Akkermansia sp. strain.
[0015] Yet another aspect of the present invention relates to a veterinary composition for preventing or treating cancer or an inflammatory disease, comprising extracellular vesicles (EVs) derived from Akkermansia sp. as an active ingredient.
[0016] Yet another aspect of the present invention relates to a novel Akkermansia muciniphila strain EB-AMDK39 (KCTC13765BP). Effect of the Invention
[0017] A pharmaceutical composition for preventing or treating cancer or inflammatory diseases, comprising the extracellular vesicles (EVs) derived from the Akkermansia strain of the present invention as an active ingredient, can be developed as an effective anticancer drug by reducing tumor size, reducing tumor growth, preventing metastasis, and preventing angiogenesis.
[0018] The pharmaceutical composition for preventing or treating cancer or inflammatory diseases comprising the Akkermansia strain of the present invention not only exhibits excellent anti-cancer effects when administered alone, but also, when administered in combination with a chemical anti-cancer agent or an immunological anti-cancer agent, reduces the side effects of the anti-cancer agent and further activates its efficacy, thereby providing even more excellent anti-cancer effects than when these are administered alone.
[0019] INDUSTRIAL APPLICABILITY The pharmaceutical composition of the present invention is highly effective in inhibiting the expression of proinflammatory cytokine genes TNF-α, IL-6 and IL-8, and can therefore be useful in the prevention or treatment of inflammatory diseases. [Brief description of the drawings]
[0020] [Figure 1] 1 shows the results of microscopic observation of the Akkermansia muciniphila EB-AMDK39 strain (KCTC13765BP) of the present invention and the type strain Akkermansia muciniphila ATCC BAA-835 strain. [Diagram 2] 1 shows the results of PCR analysis of the Akkermansia muciniphila EB-AMDK39 strain and the Akkermansia muciniphila ATCC BAA-835 strain of the present invention. [Diagram 3] 1 shows the results of a random amplified polymorphic DNA (RAPD) analysis of genomic DNA of the Akkermansia muciniphila EB-AMDK39 strain and the Akkermansia muciniphila ATCC BAA-835 strain of the present invention. [Figure 4] Phylogenetic diagram of Akkermansia muciniphila EB-AMDK39 strain based on 16S rRNA sequences. [Diagram 5] 1 shows the results of confirming whether the Akkermansia muciniphila EB-AMDK39 strain and the Akkermansia muciniphila ATCC BAA-835 strain of the present invention have hemolytic activity. [Figure 6a]6a and 6b are schematic diagrams illustrating the animal experiment process of Examples 4 and 5 to confirm the anti-cancer activity of extracellular vesicles (EVs) derived from the Akkermansia muciniphila EB-AMDK39 strain of the present invention. [Figure 6b] 6a and 6b are schematic diagrams illustrating the animal experiment process of Examples 4 and 5 to confirm the anti-cancer activity of extracellular vesicles (EVs) derived from the Akkermansia muciniphila EB-AMDK39 strain of the present invention. [Figure 7] Figures 7 and 8 are figures showing the tumor formation inhibitory effect of combined administration of the Akkermansia muciniphila EB-AMDK39 strain of the present invention and anti-PD1 in mice with allografted tumors, and are graphs showing the change in tumor volume over time in an allograft anti-cancer animal model. [Figure 8] Figures 7 and 8 are figures showing the tumor formation inhibitory effect of combined administration of the Akkermansia muciniphila EB-AMDK39 strain of the present invention and anti-PD1 in mice with allografted tumors, and are graphs showing the change in tumor volume over time in an allograft anti-cancer animal model. [Figure 9] FIG. 11 is a photograph comparing the tumor sizes of mice in each experimental group in an allograft anti-cancer animal model for 20 days to measure the cancer development inhibitory effect of combined administration of the Akkermansia muciniphila EB-AMDK39 strain of the present invention and anti-PD1 in Example 4. [Figure 10] 1 shows photographs depicting the results of immunohistochemical staining of CD4, Foxp3, and CD8 in tumors following administration of a test substance in Example 5. [Figure 11] 1 is a graph showing immunohistochemical staining for CD4, Foxp3, and CD8 in the tumor in Example 5. [Figure 12] This is a graph showing the changes in tumor size and weight over 25 days when extracellular vesicles derived from Akkermansia muciniphila EB-AMDK39 strain and anti-PD1 were administered together in an allograft anti-cancer animal model, and when anti-PD1 alone was administered. [Figure 13]FIG. 13 is a photograph comparing the tumor sizes of mice in each experimental group. [Figure 14] 13 is a photograph showing the results of immunohistochemical staining of CD4, Foxp3, and CD8 in tumors following administration of a test substance in Example 7. [Figure 15] 1 is a graph showing immunohistochemical staining for CD4, Foxp3, and CD8 in the tumor in Example 7. [Figure 16] FIG. 13 shows the administration schedule for an experiment comparing the anticancer effects of live Akkermansia muciniphila EB-AMDK39 bacteria or EV alone in an allograft mouse animal model using melanoma in Example 8. [Figure 17] 1 shows the B16-F10 tumor growth curves according to test substance concentrations in Example 8. [Figure 18] 1 is a graph showing tumor weights as a result of administration of a test substance in Example 8. [Figure 19] 1 shows photographs of tumors caused by administration of a test substance in Example 8. [Figure 20] 13 is a set of photographs showing the results of immunohistochemical staining of CD4, Foxp3, and CD8 in tumors following administration of a test substance in Example 9. [Figure 21] 1 is a graph showing immunohistochemical staining for CD4, Foxp3, and CD8 in the tumor in Example 9. [Figure 22a] Figures 22a and 22b show the results of evaluating the anticancer activity of extracellular vesicles derived from the Akkermansia muciniphila EB-AMDK39 strain of the present invention using a wound healing assay in HT29 cells. [Figure 22b] Figures 22a and 22b show the results of evaluating the anticancer activity of extracellular vesicles derived from the Akkermansia muciniphila EB-AMDK39 strain of the present invention using a wound healing assay in HT29 cells. [Diagram 23] This is a photograph comparing the expression of IL-8 mRNA, a pro-inflammatory cytokine, to measure the anti-inflammatory effect of extracellular vesicles derived from the Akkermansia muciniphila EB-AMDK39 strain of the present invention (EB-AMDK39 EV). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0021] The present invention will now be described in more detail with reference to the accompanying drawings.
[0022] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
[0023] In this specification, when a part is said to "comprise," "have," or "contain" a certain element, this does not mean to exclude other elements, but means that other elements may be further included, unless specifically stated to the contrary.
[0024] The term "patient" or "subject" as used herein refers to any organism, including humans or non-humans, to which the pharmaceutical compositions of the present invention are administered for the purposes of preventing or treating cancer. Exemplary subjects are humans, but also include mice, rats, rabbits, dogs, cats, horses, cows, pigs, deer, and non-human primates.
[0025] As used herein, the terms "treat," "treatment," and the like refer to temporarily or permanently relieving a symptom, removing the cause of a symptom, or preventing or delaying the onset of a symptom of a disease or condition.
[0026] The term "prevention" as used herein means any action of suppressing or delaying cancer or inflammation by administration of a pharmaceutical composition according to the present invention.
[0027] As used herein, the term "amelioration" refers to any action that reduces a parameter associated with an abnormal condition, such as the severity of a symptom.
[0028] As used herein, the term "pharmacologically acceptable" means a composition that is suitable for use in contact with the tissues of a subject (e.g., a human) without excessive toxicity, irritation, allergic response, or other problem or complication, with a reasonable benefit / risk ratio, and within the scope of sound medical judgment.
[0029] As used herein, the term "immune checkpoint inhibitor" refers to a class of drugs that block specific proteins produced by certain types of immune system cells, such as T lymphocytes, and some cancer cells; these proteins suppress the immune response and prevent T lymphocytes from killing cancer cells. Well-known "immune checkpoint inhibitors" to date include PD-1 / PD-L1 and CTLA-4 / B7-1 / B7-2.
[0030] As used herein, the term "combination therapy" refers to a clinical intervention in which a subject is exposed to two or more therapies (e.g., two or more therapeutic agents) simultaneously. In some embodiments, the two or more therapies can be administered simultaneously. In some embodiments, the two or more therapies can be administered sequentially. In some embodiments, the two or more therapies can be administered in overlapping administration therapy. In some embodiments, the two or more therapeutic agents of the combination therapy are administered to the subject separately, e.g., as separate compositions, via separate routes of administration (e.g., one agent orally and another agent intravenously), and / or at different times. In some embodiments, the two or more therapeutic agents can be administered in a combination composition via the same route of administration or at the same time.
[0031] One aspect of the present invention relates to a pharmaceutical composition for preventing or treating cancer or an inflammatory disease, comprising extracellular vesicles (EVs) derived from Akkermansia sp. as an active ingredient.
[0032] Pharmabiotics are defined as bacteria or their products of human origin that have a proven pharmacological role in health or disease ('Probiotics and pharmabiotics', Bioeng Bugs. 2010 Mar-Apr; 1(2): 79-84.). The pharmaceutical composition of the present invention is based on a pharmacobiotic component and can be used safely without side effects.
[0033] The Akkermansia strain may be an Akkermansia muciniphila strain. Specifically, the Akkermansia strain may be an Akkermansia muciniphila EB-AMDK39 strain (KCTC13765BP).
[0034] Extracellular vesicles (EVs) are nano-sized vesicles with a size of 20~300nm that are secreted from cells. They contain immunologically important proteins such as main histocompatibility complex (MHC) and heat shock proteins, which induce a strong anti-tumor immune response, as well as anti-inflammatory microRNAs and microRNAs that regulate collagen accumulation.
[0035] The extracellular vesicles (EVs) derived from Akkermansia sp. of the present invention simultaneously exhibit the effects of inhibiting cancer cell proliferation, reducing cancer cell mobility, and inhibiting angiogenesis, and can be used as excellent anticancer agents, and can be administered in combination with existing chemical anticancer agents or immunological anticancer agents.
[0036] The extracellular vesicles (EVs) derived from Akkermansia sp. of the present invention can be administered simultaneously with the chemical anticancer agent or immunoanticancer agent as a single formulation, or can be administered simultaneously or sequentially as separate formulations.
[0037] In the present invention, the method for separating extracellular vesicles is not limited, and for example, in a culture medium, separation can be performed using methods such as centrifugation, ultra-high speed centrifugation, filtration with a filter, gel filtration chromatography, preflow electrophoresis, capillary electrophoresis, separation using a polymer, and combinations thereof, and preferably, separation can be performed by centrifugation / ultracentrifugation. In this case, centrifugation / ultracentrifugation can be performed sequentially at 100 to 300,000 g, preferably 150 to 150,000 g, to remove cell debris, non-extracellular vesicle fractions, dead cells, etc.
[0038] Differential centrifugation The most preferred method for the separation of extracellular vesicles is differential centrifugation. This method consists of several steps, is preferably carried out at about 4° C., and includes at least the following steps 1) to 3): Step 1) Low speed centrifugation to remove cells and cell debris; Step 2) a high speed spin to remove large vesicles >100 nm; and Step 3) High speed centrifugation to pellet extracellular vesicles.
[0039] Density gradient centrifugation : This approach combines ultracentrifugation with sucrose density gradient. More specifically, density gradient centrifugation is used to separate extracellular vesicles from non-decellular particles, such as proteins and protein / RNA aggregates. Thus, this method separates vesicles from particles of other densities.
[0040] Size Exclusion Chromatography Size Exclusion Chromatography is used to separate macromolecules based on their size, rather than their molecular weight. This technique applies a column packed with porous polymer beads containing multiple pores and tunnels. Molecules pass through the beads according to their diameter. Molecules with smaller radii take longer to move through the pores of the column, so the macromolecules elute from the column sooner. Size Exclusion Chromatography allows for the precise separation of large and small molecules.
[0041] filtration Ultrafiltration membranes can also be used to isolate extracellular vesicles. Depending on the size of the microvesicles, this method allows the isolation of extracellular vesicles from proteins and other macromolecules.
[0042] Polymer-based precipitation : Polymer-based precipitation methods generally involve mixing the biological fluid with a polymer-containing precipitation solution, incubation at 4°C, and centrifugation at low speed. One of the most common polymers used in polymer-based precipitation is polyethylene glycol (PEG). Precipitation with this polymer has many advantages, including its mild effect on isolated extracellular vesicles and the use of a neutral pH.
[0043] Isolation by sieving : This technique isolates extracellular vesicles by sieving them from biological fluids through a membrane and performing filtration by pressure or electrophoresis.
[0044] The pharmaceutical composition of the present invention has excellent effects in preventing or treating cancer.
[0045] Specifically, the pharmaceutical composition of the present invention may satisfy one or more of the following characteristics: (A) CD8 in the tumor + Increase T cell levels; (B) reducing regulatory T cell levels within the tumor; (C) increasing macrophage levels within the tumor; Specifically, extracellular vesicles derived from Akkermansia sp. (hereinafter, abbreviated as "EB-AMDK39 EV") are absorbed by cancer cells, suppress EMT action, and activate the immune system to suppress the penetration and metastasis of cancer cells. EB-AMDK39 EV plays an important role in regulating T cells to activate the innate and acquired immune systems. In addition, regulatory T cells (Treg), characterized by the expression of Foxp3, are known to suppress anti-cancer immunity, interfere with protective immune surveillance of tumors, and oppose effective anti-tumor immune responses, and EB-AMDK39 EV is presumed to exhibit anti-cancer effects by activating T helper cells, activating cytotoxic T cells, and suppressing Treg cells. As a result, the pharmaceutical composition of the present invention has excellent effects in preventing, treating, and suppressing metastasis of cancer.
[0046] As used herein, the term "cancer" is meant to include tumors, neoplasias, and malignant tissues or cells. The cancers include colorectal cancer, lung cancer, small cell lung cancer, gastric cancer, liver cancer, blood cancer, bone cancer, pancreatic cancer, skin cancer, head or neck cancer, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, perianal cancer, colon cancer, breast cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, Hodgkin's disease, esophageal cancer, small intestine cancer, endocrine gland cancer, thyroid cancer, parathyroid cancer, adrenal gland cancer, soft tissue sarcoma, urethral cancer, penile cancer, prostate cancer, chronic or acute leukemia, lymphocytic lymphoma, bladder cancer, kidney cancer, ureteral cancer, renal cell carcinoma, renal pelvic cancer, CNS tumor, primary CNS lymphoma, spinal cord tumor, brain stem glioma, pituitary adenoma, or a combination of two or more of these cancers.
[0047] In the present invention, the extracellular vesicles (EVs) derived from the Akkermansia strain according to the present invention, which are contained as an active ingredient in the pharmaceutical composition, have an average diameter of 20 to 300 nm.
[0048] The effective amount of the extracellular vesicles derived from Akkermansia strains in the pharmaceutical composition according to the present invention may vary depending on the age, sex, and body weight of the patient. In general, 0.001 to 150 mg, preferably 0.01 to 100 mg per kg of body weight can be administered daily or every other day, or in divided doses once to three times a day.
[0049] The pharmaceutical composition according to the present invention can be used as a single anti-cancer therapy. Also, the pharmaceutical composition according to the present invention can be used simultaneously, separately or sequentially with a radiation or chemo-anti-cancer agent or an immuno-anti-cancer agent, depending on the situation. The combination therapy according to the present invention is for use in reducing tumor size or preventing tumor growth in the treatment of cancer. The combination therapy according to the present invention is for use in at least one of reducing tumor size, reducing tumor growth, preventing metastasis, or preventing angiogenesis.
[0050] Specifically, the pharmaceutical composition of the present invention may be administered as an individual therapeutic agent, or may be administered in combination with radiation therapy or other therapeutic agents, or may be administered sequentially or simultaneously with conventional radiation therapy or anticancer drug therapy. It may also be administered in a single dose or multiple doses. Taking all of the above factors into consideration, it is important to administer the minimum amount that provides maximum efficacy without side effects.
[0051] In some embodiments, the cancer therapeutic agent is an immunotherapy. Immunotherapy refers to a therapy that uses the immune system of a subject to treat cancer, such as checkpoint inhibitors, cancer vaccines, cytokines, cell therapy, CAR-T cells, and dendritic cell therapy. Non-limiting examples of immunotherapy are immune checkpoint inhibitors, including nivolumab (BMS, anti-PD1-1), pembrolizumab (Merck, anti-PD1-1), ipilimumab (BMS, anti-CTLA-4), MEDI4736 (AstraZeneca, anti-PD1-L1), and MPDL32280A (Roche, anti-PD1-L1). Other immunotherapies can be tumor vaccines, such as Gardasil, Cerevarix, BCG, sipulencel-T, Gp100:209-217, AGS-003, DCVax-L, Algenpantucel-L, Tergenpantucel-L, TG4010, ProstAtak, Prostvac-V / RTRICOM, Rindopepimul, E75 peptide acetate, IMA901, POL-103A, Belagenpumatucel-L, GSK1572932A, MDX-1279, GV1001, and Tecmotide. Immunotherapies can be administered via injection (e.g., intravenously, intratumorally, subcutaneously, or into lymph nodes), but may also be administered orally, topically, or via aerosol. Immunotherapies can include adjuvants, such as cytokines.
[0052] In some embodiments, the immunotherapeutic agent is an immune checkpoint inhibitor. Immune checkpoint inhibition broadly refers to inhibiting checkpoints that cancer cells can produce to prevent or downregulate immune responses. Examples of immune checkpoint proteins include, but are not limited to, CTLA4, PD-1, PD-L1, PD-L2, A2AR, B7-H3, B7-H4, BTLA, KIR, LAG3, TIM-3, or VISTA. The immune checkpoint inhibitor can be an antibody or an antigen-binding fragment thereof that binds to and inhibits the immune checkpoint protein. Examples of immune checkpoint inhibitors include, but are not limited to, nivolumab, pembrolizumab, pidilizumab, AMP-224, AMP-514, STI-A1110, TSR-042, RG-7446, BMS-936559, MEDI-4736, MSB-0020718C, AUR-012, and STI-A1010.
[0053] Unlike conventional chemotherapies that directly kill cells, immune checkpoint inhibitors have been in the spotlight as next-generation anticancer drugs that cause fewer side effects from anticancer chemotherapy, such as hair loss, anemia, and bone marrow suppression, which reduce the quality of life of cancer patients. However, immune checkpoint inhibitors have a very low response rate to some cancers (e.g., gastric cancer, colon cancer, ovarian cancer, pancreatic cancer, etc.), and are known to cause severe immune-related abnormal reactions, such as enteritis, hepatitis, pneumonia, hypothyroidism, and hypophysitis. Side effects of using immune checkpoint inhibitors are mainly minor, but in rare cases, they have been reported to be serious and fatal when they occur in the nervous system or cardiac system. The pharmaceutical composition containing extracellular vesicles derived from the Akkermansia strain of the present invention can overcome the response rate limit of immune checkpoint inhibitors, minimize side effects, and enhance anticancer effects.
[0054] The pharmaceutical composition of the present invention inhibits the secretion of cytokines (IL-8) involved in inflammation and allergies, and therefore can be useful as a pharmaceutical composition or cosmetic composition for preventing or treating inflammation.
[0055] In the present invention, the inflammatory disease may be any selected from the group consisting of edema, dermatitis, allergy, conjunctivitis, periodontitis, allergic and non-allergic rhinitis, otitis media, pharyngitis, tonsillitis, pneumonia, gastric ulcer, chronic and acute gastritis, Crohn's disease, colitis, chronic and acute enteritis, hemorrhoids, gout, ankylosing spondylitis, rheumatism, psoriatic arthritis, osteoarthritis, rheumatoid arthritis, periarthritis of the shoulder, tendonitis, tendonitis, myositis, acute and chronic hepatitis, cystitis, acute and chronic nephritis, Sjogren's syndrome, multiple sclerosis, chronic and acute rhinitis, chronic obstructive pulmonary disease, pulmonary fibrosis, viral infection, bacterial infection, fungal infection, arthritis, Hodgkin's disease, pancreatitis, iritis, scleritis, uveitis, and eczema.
[0056] The Akkermansia muciniphilla EB-AMDK39 strain of the present invention, with accession number KCTC13765BP, has a 16S rRNA gene of SEQ ID NO: 1. Closely related strains of the Akkermansia muciniphilla EB-AMDK39 strain, such as bacterial strains having a 16S rRNA sequence that is 90%, 91%, 92%, 93%, 94%, 95%, 96% or 97% identical to the 16S rRNA sequence of the Akkermansia muciniphilla EB-AMDK39 strain, can also be used as part of a therapeutic combination.
[0057] The Akkermansia muciniphilla EB-AMDK39 strain used in the present invention was isolated from the feces of a healthy Korean individual, and is a mucin-degrading bacterium that is an oval cell with an average diameter of 20-300 nm, a monococcus or diplococcus, an anaerobic bacterium, non-motile, Gram-negative, and does not form endo-spores. The Akkermansia muciniphilla EB-AMDK39 strain can produce several mucus-degrading enzymes to use mucus as a carbon and nitrogen source, can metabolize various carbon sources including glucose, galactose, N-acetylglucosamine, and lactose, and produces short-chain fatty acids such as propionic acid and acetic acid as major metabolic products.
[0058] The pharmaceutical composition for preventing or treating cancer or inflammatory diseases of the present invention may further comprise Akkermansia muciniphilla EB-AMDK39 strain, which may be selected from the group consisting of cells of the strain, disrupted cells of the strain, a culture of the strain, a culture medium in which the cells have been removed from the culture of the strain, an extract of the cells of the strain, an extract of the culture of the strain, and an extract of the culture medium in which the cells have been removed from the culture of the strain.
[0059] The Akkermansia muciniphilla EB-AMDK39 strain of the present invention can be cultured, collected by a separation process such as centrifugation, and dried, for example, by freeze-drying, to produce a live bacterial agent for use. Pasteurization of the Akkermansia muciniphilla strain refers to heating at a temperature of 50°C or higher and lower than 100°C for 10 minutes or more. For example, pasteurization can be performed at 70°C for 30 minutes.
[0060] In one embodiment of the present invention, the pharmaceutical composition containing the extracellular vesicles derived from the Akkermansia muciniphila EB-AMDK39 strain can be formulated and used in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups or aerosols, topical preparations, suppositories or sterile injection solutions by conventional methods, but is not necessarily limited to these.
[0061] In some embodiments, pharmaceutical compositions of the present invention include, but are not necessarily limited to, aqueous liquid dispersions, self-emulsifying dispersions, solid solutions, liposomal dispersions, aerosols, solid forms, powders, immediate release formulations, controlled release formulations, fast melt formulations, tablets, capsules, pills, delayed release formulations, sustained release formulations, pulsatile release formulations, multiparticulate formulations, and mixed immediate and controlled release formulations.
[0062] For intravenous, intratumoral or intranasal administration, aqueous suspensions containing pharmacologically compatible dispersants and / or wetting agents, isotonic saline solutions, or sterile injectable solutions can be used. As excipients, water, alcohol, polyols, glycerol, vegetable oils, etc. can be used.
[0063] The pharmaceutical composition of the present invention can be formulated as a product for enteral or oral administration. In addition, the pharmaceutical composition of the present invention can be enterically coated by a known method so that the active ingredient, extracellular vesicles (EVs), can be rapidly released in the intestine after passing through the stomach and reaching the small intestine.
[0064] The pharmaceutical composition of the present invention may further contain a pharma- ceutically acceptable carrier and / or excipient in addition to the active ingredient, and may be formulated with various additives commonly used in pharmaceuticals, such as binders, disintegrants, coating agents, lubricants, etc.
[0065] The pharma- ceutically acceptable carrier may further include, for example, a carrier for oral administration or a carrier for parenteral administration. Carriers for oral administration include lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. In addition, various drug delivery substances used for oral administration may be included. Carriers for parenteral administration may also include water, suitable oils, saline, aqueous glucose, and glycols, and the like. The pharmaceutical composition of the present invention may further include a stabilizer and a preservative. Suitable stabilizers include antioxidants such as sodium bisulfite, sodium sulfite, or ascorbic acid. Suitable preservatives include benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol. The pharma- ceutically acceptable carriers and formulations that may be included in the pharmaceutical composition of the present invention may be referred to in the following documents (Remington's Pharmaceutical Sciences, 1999, pp. 111-115, 2001). th ed., Mack Publishing Company, Easton, PA, 1995).
[0066] Excipients that can be used in the present invention include sugars such as sucrose, lactose, mannitol, glucose, etc., and starches such as corn starch, potato starch, rice starch, partially pregelatinized starch, etc. Binders include polysaccharides such as dextrin, sodium alginate, carrageenan, guar gum, acacia, agar, etc., natural macromolecular substances such as tragacanth, gelatin, gluten, etc., cellulose derivatives such as hydroxypropyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose, ethyl cellulose, hydroxypropyl ethyl cellulose, sodium carboxymethyl cellulose, etc., and polymers such as polyvinylpyrrolidone, polyvinyl alcohol, polyvinyl acetate, polyethylene glycol, polyacrylic acid, polymethacrylic acid, and vinyl acetate resins.
[0067] Examples of disintegrants that can be used in the present invention include cellulose derivatives such as carboxymethylcellulose, calcium carboxymethylcellulose, and low-substituted hydroxypropylcellulose, and starches such as sodium carboxymethyl starch, hydroxypropyl starch, corn starch, potato starch, rice starch, and partially pregelatinized starch.
[0068] Examples of lubricants that can be used in the present invention include talc, stearic acid, calcium stearate, magnesium stearate, colloidal silica, hydrous silicon dioxide, various types of waxes and hydrogenated oils.
[0069] Examples of coating agents include, but are not limited to, water-insoluble copolymers such as dimethylaminoethyl methacrylate-methacrylic acid copolymer, polyvinyl acetal diethylamino acetate, ethyl acrylate-methacrylic acid copolymer, ethyl acrylate-methyl methacrylate-chlorotrimethylammonium ethyl methacrylate copolymer, and ethyl cellulose, methacrylic acid-ethyl acrylate copolymer, enteric polymers such as hydroxypropyl methylcellulose phthalate and hydroxypropyl methylcellulose acetate succinate, and water-soluble polymers such as methylcellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone, and polyethylene glycol.
[0070] The dosage of the Akkermansia-derived extracellular vesicles as an active ingredient in the pharmaceutical composition for preventing or treating cancer or inflammatory diseases of the present invention can be determined based on factors including the type of disease, the patient's age, weight, sex, medical condition, severity of condition, sensitivity to drugs, administration time, administration route and excretion rate, treatment period, drugs used simultaneously, and other factors well known in the medical field. Thus, although dosage regimens can vary widely, it is important to administer the minimum amount that provides maximum efficacy without side effects, taking into account all of these factors, which can be easily determined by those skilled in the art using standard methods.
[0071] Another aspect of the present invention relates to a health functional food comprising extracellular vesicles (EVs) derived from Akkermansia sp. strains. The EVs are preferably Akkermansia muciniphila EB-AMDK39 strain-derived EVs. The health functional food of the present invention can be used for the prevention or improvement of cancer or inflammatory diseases.
[0072] The health functional food of the present invention includes all forms such as functional foods, nutritional supplements, health foods, food additives, and feeds.
[0073] The above-mentioned types of health functional foods can be prepared in various forms according to conventional methods known in the art. General foods include, but are not limited to, beverages (including alcoholic beverages), fruits and processed foods thereof, fish, meat and processed foods thereof, breads and noodles, fruit juices, various drinks, cookies, candies, dairy products, edible vegetable oils and fats, margarine, vegetable proteins, retort foods, frozen foods, various sauces, etc., and can be prepared by adding extracellular vesicles derived from the Akkermansia genus EB-AMDK39 strain.
[0074] In addition to the above, the health functional food of the present invention may contain various nutrients, vitamins, electrolytes, flavorings, colorants, pectinic acid, salts of pectinic acid, alginic acid, salts of alginic acid, organic acids, protective colloid thickeners, pH regulators, stabilizers, preservatives, glycerin, alcohol or carbonation agents, etc.
[0075] Another aspect of the present invention relates to a method for treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of extracellular vesicles derived from an Akkermansia strain of the present invention.
[0076] Another aspect of the present invention relates to a veterinary composition for preventing or treating cancer or inflammatory disease, comprising extracellular vesicles (EVs) derived from Akkermansia sp. as an active ingredient. Here, the animal may refer to, but is not limited to, pets such as dogs, cats, guinea pigs, hamsters, rats, mice, ferrets, rabbits, etc. The veterinary composition may be a veterinary drug or feed additive.
[0077] The present invention provides a novel Akkermansia sp. EB-AMDK39 strain, which was deposited at the Korea Institute of Bioscience and Biotechnology, Korea Bioresource Center on December 5, 2018 under the accession number KCTC13765BP.
[0078] The present invention will be described in detail below with reference to examples. However, these examples are merely illustrative of the present invention, and the content of the present invention is not limited to these examples.
[0079] Working Example Example 1: Akkermansia muciniphila Isolation and identification of the Muciniphilla EB-AMDK39 strain 1. Strain Isolation and Identification To isolate Akkermansia muciniphila genus from feces of a healthy Korean female (7 years old, BMI 19.9), the strain was selectively cultured in an anaerobic chamber under strict anoxic conditions (5% H2, 15% CO2, and 80% N2) using mucin medium (0.4 g / L monopotassium phosphate, 0.53 g / L sodium dichlorophosphate, 0.3 g / L sodium chloride, 0.3 g / L aluminum chloride, 0.1 g / L magnesium chloride, 0.11 g / L calcium chloride, 4 g / L sodium bicarbonate, 1 mL acidic trace element solution, 1 mL alkaline trace element solution, 1 mL vitamin solution, 2.5 g / L porcine gastric mucus (Type III)), and 0.25 g / L sodium sulfide nonahydrate) according to the method of Derrien (Derrien et al., 2004, Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium, International Journal of Systematic and Evolutionary Microbiology, 54: 1469-1476).
[0080] 1.2.Microscopic Observation To confirm whether the isolated strains were Akkermansia strains, the isolated strains were observed under a microscope. In Fig. 1, A is the A. muciniphila ATCC BAA-835 type strain, and B is a micrograph of the A. muciniphila EB-AMDK39 strain enlarged at 1000 times. As shown in Fig. 1, the type strains A. muciniphila ATCC BAA-835 type strain (A) and A. muciniphila EB-AMDK39 strain (B) were observed at 1000 times magnification, and it was confirmed that these strains were both straight or curved rod-shaped cells and had similar shapes to each other.
[0081] 1.3. PCR analysis To confirm whether the isolated strains were Akkermansia strains, PCR analysis was performed using the AM-specific primers (SEQ ID NO: 2 and SEQ ID NO: 3) in Table 1 below, and the results are shown in Figure 2. In Figure 2, lane M is the DNA size marker, lane 1 is the positive control (ATCC BAA-835), lane 2 is the Akkermansia muciniphila EB-AMDK39 strain, and lane 3 is the negative control (distilled water).
[0082] As shown in FIG. 2, it can be confirmed that the Akkermansia muciniphila EB-AMDK39 strain of the present invention exhibited a similar band pattern to that of the Akkermansia muciniphila ATCC BAA-835 standard strain.
[0083] [Table 1]
[0084] 1.4. RAPD (Random Amplified Polymorphic DNA) analysis To verify the similarity between the Akkermansia muciniphilla EB-AMDK39 strain isolated as described above and the previously reported Akkermansia muciniphilla ATCC BAA-835 standard strain, a type of molecular typing, RAPD was performed. For this purpose, genomic DNA extracted from the fungus was amplified using the universal primers in Table 2 below, and then electrophoresed on a 1% agarose gel for 1 hour and 30 minutes, and the DNA fragmentation patterns were compared on a UV perforator. The results are shown in Figure 3.
[0085] [Table 2]
[0086] As can be seen from Figure 3, the Akkermansia muciniphila EB-AMDK39 strain of the present invention showed a different RAPD band pattern when compared with the Akkermansia muciniphila ATCC BAA-835 standard strain. It is known that the RAPD band pattern of Akkermansia muciniphila differs depending on the species, and it was confirmed that the Akkermansia muciniphila EB-AMDK39 strain of the present invention belongs to the same species as the Akkermansia muciniphila ATCC BAA-835 standard strain, but is a different strain.
[0087] 1.5.Total length 16S Phylogenetic tree based on rRNA gene sequences Tree analysis In order to analyze the full-length 16S rRNA gene sequence of the Akkermansia muciniphilla EB-AMDK39 strain isolated as described above, the 16S rRNA gene was amplified using the 27F and 1541R primers in Table 3 below, and the sequence was determined using a 3730x1 DNA analyzer. Based on the 16S rRNA gene sequences of the Akkermansia muciniphilla EB-AMDK39 strain of the present invention and other previously published strains of the genus Akkermansia, a phylogenetic analysis was performed using MEGA-X. A phylogenetic tree was constructed by the neighbor-joining method using 1000 bootstraps and is shown in Figure 4(A). The average nucleotide identity (ANI) value was evaluated by applying the pyani v0.2.7 program with the -m ANIb setting to evaluate the evolutionary distance. Akkermansia muciniphilla ATCC BAA-835 strain (Accession number: GCF_000020225.1), Akkermansia muciniphilla CBA5201 strain (Accession number: GCF_004104435.1), Akkermansia muciniphilla JCM30893 strain (Accession number: GCF_009731575.1), Akkermansia muciniphilla EB-AMDK19 strain (Accession number: GCF_004015105.1), The whole or draft genome sequences of Akkermansia muciniphila EB-AMDK27 strain (Accession No.: GCF_010223015.1) and Akkermansia glycaniphila PytT strain (Accession No.: GCF_900097105.1) were downloaded from the NCBI Genome Database (https: / / www.ncbi.nlm.nih.gov / genome / ). A phylogenetic tree was constructed using the 16S rRNA gene sequences of other strains of the same species, as shown in Figure 4(B).
[0088] [Table 3]
[0089] As shown in Figures 4(a) and 4(b), the phylogenetic tree showing the evolutionary relationships was analyzed through the analysis of the 16s rRNA gene base sequence, and it was confirmed that the Akkermansia muciniphila EB-AMDK39 strain is a strain genetically belonging to Akkermansia muciniphila.
[0090] The Akkermansia muciniphila EB-AMDK39 strain of the present invention isolated from human feces was identified through biochemical methods (API) and molecular biological methods (16S rRNA sequence analysis, 16S rRNA BLAST analysis, RAPD) using Akkermansia muciniphila (ATCC BAA-835) as a control, and confirmed to be a safe strain capable of probiotic function through an antibiotic resistance test described below. Based on these results, the isolated Akkermansia muciniphila strain was named Akkermansia muciniphila EB-AMDK39 strain and was deposited at the Korea Biological Resource Center (KCTC) and assigned the accession number KCTC13765BP.
[0091] Example 2: Analysis of the mycological characteristics and safety of Akkermansia muciniphila EB-AMDK39 strain 2.1. Isolation of Akkermansia sp. Confirmation of sugar utilization ability of the strain In order to examine the sugar utilization of the Akkermansia muciniphila EB-AMDK39 strain of the present invention isolated above, the strain was cultured using an API50CH kit (Biomerieux, France), and the growth using each sugar was compared with that of the Akkermansia muciniphila standard strain (ATCC BAA-835). The results are shown in Table 4 below.
[0092] [Table 4]
[0093] As can be seen from Table 4, the Akkermansia muciniphilla EB-AMDK39 strain of the present invention was found to have a difference in the ability to utilize ribose, D-galactose, D-fructose, D-mannose, D-lactose and L-fucose when compared with the standard Akkermansia muciniphilla strain (ATCC BAA-835).
[0094] 2.2. Confirmation of antimicrobial susceptibility of isolated strains To examine the antimicrobial susceptibility of the A. muciniphila EB-AMDK19 strain isolated as described above, the minimum inhibitory concentration (MIC) of the strain against anaerobic antimicrobial agents (piperacillin-tazobactam (PTZ), ceftizoxime (CTZ), chloramphenicol (CHL), clindamycin (CLI), meropenem (MEM), moxifloxacin (MXF), metronidazole (MTZ), and ciprofloxacin (CIP)) was determined by the broth microdilution method of the Clinical & Laboratory Standard Institute (CLSI) guidelines (CLSI, 2017), and the results are shown in Table 5 below.
[0095] [Table 5]
[0096] As can be seen from Table 5, the Akkermansia muciniphila EB-AMDK39 strain of the present invention was resistant to ceftizoxime, clindamycin, and fluoroquinolone antibiotics moxifloxacin and ciprofloxacin, and was sensitive to the other antibiotics. There were some differences in the antibiotic resistance pattern when compared with the standard strain. Resistance to fluoroquinolone antibiotics is a resistance that exists in the same Akkermansia muciniphila, and is considered to be an intrinsic resistance.
[0097] Furthermore, the complete full-length genome of the Akkermansia muciniphila EB-AMDK39 strain of the present invention was subjected to bioinformatics-based PlasmidFinder (https: / / cge.cbs.dtu.dk / services / PlasmidFinder / ), PHASTER (https: / / phaster.ca / ), and Mobile Element Finder (cge.cbs.dtu.dk / services / MobileElementFinder) programs to confirm whether acquired / endogenous genes exist. As a result, no plasmid was present in the Akkermansia EB-AMDK39 strain, and no acquired / endogenous antibiotic resistance-related genes were detected. Therefore, it can be confirmed that the Akkermansia EB-AMDK39 strain of the present invention is a safe strain.
[0098] 2.3. Hemolytic activity of isolated strains analysis of activity) and virulence factors To verify the safety of the Akkermansia muciniphila EB-AMDK39 strain isolated as described above, we evaluated whether it had hemolytic activity. To this end, the strain was cultured on a blood agar medium prepared by adding 5% w / v defibrinated cryp blood to tryptic soy agar (17.0 g / L casein pancreatic digest, 3.0 g / L soybean pancreatic digest, 2.5 g / L dextrose, 5.0 g / L sodium chloride, 2.5 g / L potassium phosphate, 15 g / L agar), and the results are shown in Figure 5. As can be seen from Figure 5, the Akkermansia muciniphila EB-AMDK39 strain of the present invention did not show β-hemolysis (completely transparent areas around the colony) related to pathogenicity.
[0099] Based on the pathogenic strain database VFDB (reference database for bacterial virulence factors, http: / / www.mgc.ac.cn / VFs), genes encoding virulence factors were investigated on the full-length genome of the Akkermansia muciniphila EB-AMDK39 strain of the present invention. The analysis was performed under the following analysis conditions: protein identity of at least 80%, coverage of at least 80%, and alignment length of at least 50 bp. As a result of the analysis, no virulence factors were detected in the Akkermansia genus EB-AMDK39 strain. This indicates that the Akkermansia muciniphila EB-AMDK39 strain is harmless in the human body.
[0100] 2.4. Confirmation of the short-chain fatty acid (SCFA) production ability of Akkermansia muciniphila strains Short chain fatty acids (SCFAs), such as butyrate, acetate, and propionate, are metabolic products produced by intestinal bacteria and play an important role in the host's energy metabolism. They are signaling mediators that act on G protein-coupled receptors (GPR41 and GPR43) and are involved in energy balance.
[0101] Short-chain fatty acids (SCFAs) decrease intestinal motility and increase intestinal transit rate through GPR41 in enteroendocrine cells. This induces PYY (peptide YY) secretion, which reduces energy intake and prevents obesity. In addition, GPR43 by short-chain fatty acids increases satiety through increasing insulin sensitivity by inducing GPL-1 (glucagon-like peptide 1), and GPR43 activity suppresses insulin signaling from adipose tissue to prevent fat accumulation. Short-chain fatty acids (SCFAs) can improve glucose metabolism and activate intestinal gluconeogenesis (IGN), which can reduce food intake through the gut-brain neural circuit. Furthermore, vitamin B12 affects the short-chain fatty acid production ability of the strain. Specifically, it can act as a coenzyme that catalyzes the conversion of succinic acid to propionic acid. The Akkermansia muciniphila strain of the present invention has methylmalonyl-coA mutase that catalyzes the conversion of succinic acid to propionic acid using vitamin B12 as a cofactor.
[0102] In the above example, in order to confirm the gene composition that plays a direct role in the synthesis of vitamin B12 specific to A. muciniphila EB-AMDK39 strain and to confirm the change in functional metabolites of A. muciniphila strains depending on the presence or absence of vitamin B12 during cultivation, the short chain fatty acid (SCFA) content in the culture solution was analyzed by gas chromatography (GC) after culturing in a test tube. For this purpose, the culture solution was centrifuged at 12,000×g for 5 minutes to collect the supernatant. The supernatant was filtered using a 0.2 μm syringe filter and then used for analysis. A gas chromatograph (Agilent 7890N) equipped with a FFAP column (30 m×0.320 mm, 0.25 μm phase) was used. The conditions were set as shown in Table 6. The analysis results are shown in Table 7 below.
[0103] [Table 6]
[0104] [Table 7]
[0105] As can be seen from Table 7, the Akkermansia muciniphila EB-AMDK39 strain of the present invention exhibited a different short-chain fatty acid production ability from Akkermansia muciniphila ATCC BAA-835 (standard strain). In detail, when vitamin B12 was not added to the culture medium, the main short-chain fatty acids of Akkermansia muciniphila ATCC BAA-835 were acetic acid and succinic acid, whereas the Akkermansia muciniphila EB-AMDK39 strain of the present invention, regardless of the presence or absence of vitamin B12, mainly produced acetic acid and propionic acid, and in particular, the amount of propionic acid produced was confirmed to be about 40 times higher than that of the standard strain. From the above results, it can be seen that the Akkermansia muciniphila EB-AMDK39 strain of the present invention has a clear difference in short-chain fatty acid production ability from the Akkermansia muciniphila ATCC BAA-835 standard strain due to the presence or absence of vitamin B12.
[0106] Example 3: Isolation of extracellular vesicles from Akkermansia muciniphila strains To obtain extracellular vesicles (EVs) of A. muciniphila EB-AMDK39 strain, the culture medium of A. muciniphila EB-AMDK39 strain was centrifuged at 10,000×g and 4℃ for 20 minutes, and the supernatant was collected and filtered using 0.45μm and 0.22μm filters. The filtered supernatant was centrifuged at 150,000×g and 4℃ for 2 hours to obtain a pellet, which was then dissolved in sterile saline (PBS) and subjected to protein quantification before being used in the efficacy test.
[0107] Example 4: aPD-1 immunotherapy in a melanoma allograft mouse animal model and Anticancer effect of combined administration with live Akkermansia muciniphila EB-AMDK39 bacteria 4.1. Strain samples The live Akkermansia muciniphila EB-AMDK39 (KCTC13765BP) bacteria used in this experiment were 1 × 10 8 The cells were prepared at a concentration of CFU / 150 μl of PBS (25% glycerol, 0.05% cysteine / PBS).
[0108] Animal testing Animal experiments were performed in accordance with the Animal Use and Care Protocol of the IACUC (Institutional Animal Care and Use Committee). For cancer induction, 8-week-old female C57BL / 6 mice were purchased and allowed to adapt for one week, after which they were housed for five weeks. The housing environment was maintained at a constant temperature (22°C) and relative humidity (40-60%), with light and dark cycles controlled on a 12-hour cycle.
[0109] To establish a syngeneic mouse anti-cancer animal model, mouse-derived melanoma cells (B16-F10) were used.
[0110] The allograft model is a technique in which a mouse cell line grown in vitro is transplanted into an actual mouse and grown there. Since the same host and cell line are used, there is no risk of tumor rejection.
[0111] After one week of acclimatization, the mice were pretreated with the antibiotics shown in Table 8 for one week.
[0112] [Table 8]
[0113] Next, 2 × 10 4 B16-F10 cells were injected subcutaneously (SC) into the thigh of mice together with 100 μl of Matrigel.
[0114] 4.3. Sample administration and experimental group setting Each drug shown in Table 9 below was orally administered to mice every day for 5 weeks. As a positive control group, anti-PD1 antibody was orally administered at 250 μg / 100 μl / head.
[0115] Cancer cells began to appear on day 6, and from this point on, A. muciniphila EB-AMDK39 strain was added to the culture medium for 10 min. 8 CFU were orally administered daily. From the sixth day, 250μg of aPD-1 antibody was intraperitoneally injected every four days. In this case, the aPD-1 antibody used was InVivoMab anti-mouse PD-1 (RMP1-14), catalog #BE0146, from BioX Cell Lines. It was diluted to a concentration of 250μg / 100μl using InVivoPure pH7.0 Dilution Buffer, catalog #IP0070.
[0116] During tumor growth, mice were weighed twice a week and monitored daily, and tumor size was monitored every other day using a computerized caliper starting on day 6, when cancer cells began to appear (see FIG. 6a).
[0117] Tumor volume was calculated by measuring the two diameters (longest and shortest diameters) of each tumor according to the following formula:
[0118]
number
[0119] [Table 9]
[0120] 7 to 9, it was confirmed that the tumor size was significantly smaller in the group orally administered live Akkermansia muciniphila EB-AMDK39 bacteria compared to the control group allografted with B16-F10 cells. The tumor size in the normal control group was 452.4 ± 69.7 mm. 3 In comparison, the tumor size in the aPD-1 treated group was 274.7 ± 50.7 mm 3 , (p<0.05) (80% reduction), and in the group administered aPD-1 in combination with Akkermansia muciniphila EB-AMDK39, the mean mean mean was 91.5±15.19 mm 3 , (P<0.01) (39% decrease). In particular, the aPD-1 + EB-AMDK39 combination treatment group showed a significant tumor suppression effect of approximately 67% compared to the aPD-1 treatment group (p<0.05).
[0121] Example 5: Changes in intratumoral immune cells by combined administration of aPD-1 immunotherapy and live Akkermansia muciniphila EB-AMDK39 in a melanoma allograft mouse animal model To confirm the activity of immune cells in the tumor tissue, immunohistochemistry (IHC) was performed for CD4, Foxp3, and CD8. Expression patterns were confirmed by microscopic examination, and the image analysis software Image J was used to measure the DAB color-positive area, which is indicated by yellow-brown or yellow-red. The positive areas (CD4, Foxp3, and CD8 positive cells) in each microscopic photograph were measured and compared, and the results are shown in graphs in Figures 10 and 11.
[0122] As shown in Figures 10 and 11, the immune activity in the tumor was confirmed by measuring the ratio of CD4 positive T cells and Foxp3 positive Treg cells. As a result, in the aPD-1+EB-AMDK39 combination treatment group, the increase in FoxP3 positive regulatory T cells (Treg) was suppressed, and the CD4 / Treg ratio was significantly higher than in the other treatment groups. This confirmed that the combination of aPD-1 and EB-AMDK39 reduced Treg cell activity and increased CD4 T cell activity. The above results indicate that the combination of Akkermansia muciniphila EB-AMDK39 strain and anti-PD-L1 antibody further enhanced the anti-tumor immune cell activation effect.
[0123] Example 5: Changes in intratumoral immune cells by combined administration of aPD-1 immunotherapy and live Akkermansia muciniphila EB-AMDK39 in a melanoma allograft mouse animal model To confirm the activity of immune cells in the tumor tissue, immunohistochemistry (IHC) was performed for CD4, Foxp3, and CD8. Expression patterns were confirmed by microscopic examination, and the DAB-positive areas, which were shown in yellow-brown or yellow-red, were measured using the image analysis software Image J. The positive areas (CD4, Foxp3, and CD8 positive cells) in each microscopic photograph were measured and compared, and the results are shown in graphs in Figures 10 and 11.
[0124] Referring to Figures 10 and 11, the immune activity in the tumor was confirmed by measuring the ratio of CD4 positive T cells and Foxp3 positive Treg cells. As a result, in the aPD-1+EB-AMDK39 co-administration group, the increase of Foxp3 positive regulatory T cells (Treg) was suppressed, and the CD4 / Treg ratio was confirmed to be significantly higher than other treatment groups. This confirms that the co-administration of aPD-1 and EB-AMDK39 reduces Treg cell activity and increases CD4 T cell activity. The above results indicate that the co-administration of Akkermansia muciniphila EB-AMDK39 strain and anti-PD-L1 antibody further enhances the anti-tumor immune cell activation effect.
[0125] Example 6: Anticancer effect of combined administration of aPD-1 immunotherapy and extracellular vesicles (EVs) derived from Akkermansia muciniphila EB-AMDK39 in a melanoma allograft mouse animal model From the sixth day when cancer cells began to appear, 250μg of aPD-1 antibody and 100μg of extracellular vesicles (EVs) derived from Akkermansia muciniphila EB-AMDK39 strain were intraperitoneally injected every four days. The aPD-1 antibody used was InVivoMab anti-mouse PD-1 (RMP1-14), catalog #BE0146, from BioX Cell Lines. The antibody was diluted to a concentration of 250μg / 100μl using InVivoPure pH7.0 Dilution Buffer, catalog #IP0070.
[0126] The tumor size was monitored every two days from the time the tumor was measured, and the tumor size was calculated according to Formula 1, and the results are shown in the graph in Figure 12. The extracellular vesicles were tested for their efficacy alone or in the presence or absence of anti-PD1 in mouse tumor models.
[0127] 12 and 13, it was confirmed that the tumor size was significantly smaller in the group orally administered extracellular vesicles (EVs) derived from Akkermansia muciniphila EB-AMDK39 strain compared to the control group allografted with B16-F10 cells. The tumor size in the normal control group was 664.4±178.8 mm 3 In comparison, the aPD-1 group had a mean mean of 445.3 ± 148.1 mm 3 The group administered PD-1 in combination with extracellular vesicles (EVs) derived from Akkermansia muciniphila EB-AMDK39 showed a reduction of approximately 33%, and the group administered PD-1 in combination with extracellular vesicles (EVs) derived from Akkermansia muciniphila EB-AMDK39 showed a reduction of 150.7 ± 37.52 mm 3 The tumor growth was significantly inhibited by about 77% (P<0.05).
[0128] As described above, the present inventors confirmed the effect of Akkermansia sp.-derived extracellular vesicles (EVs) and anti-PD1 immune checkpoint inhibitors on cancer cell growth and metastasis in vivo, and confirmed that tumor size and weight were effectively reduced when Akkermansia sp.-derived extracellular vesicles (EVs) and anti-PD1 immune checkpoint inhibitors were injected into tumor-implanted mice (see Figures 12 and 13). Therefore, the pharmaceutical composition of the present invention has a significantly superior tumor growth inhibitory effect compared to administration of anti-PD1 alone, and can be usefully used as a pharmaceutical composition for preventing or treating cancer.
[0129] Example 7: Changes in intratumoral immune cells by combined administration of aPD-1 immunotherapy and extracellular vesicles (EVs) derived from Akkermansia muciniphila EB-AMDK39 in a melanoma allograft mouse animal model Immunohistochemical staining was performed to confirm changes in immune cell activity in tumor tissue following the combined administration of aPD-1 immunotherapy and extracellular vesicles (EVs) derived from Akkermansia muciniphila EB-AMDK39 in a melanoma allograft mouse animal model.
[0130] To confirm the activity of immune cells in the tumor tissue, immunohistochemistry (IHC) analysis was performed for CD4, Foxp3, and CD8.
[0131] Immunohistochemical staining was performed on formalin-fixed / paraffin-embedded tissues using murine anti-CD4, anti-CD8, and anti-Foxp3 antibodies. Expression patterns were confirmed by microscopic examination, and analysis was performed using image analysis software Image J to measure DAB-positive areas (CD4, Foxp3, and CD8 positive cells) shown in reddish brown or reddish yellow. The positive areas in each microscopic photograph were measured and compared, and the results are shown in the graph in Figure 14.
[0132] Figure 14 shows the IHC (immunohistochemistry) results of tumor cells after administration of the test substance. In Figure 14, yellow-brown or yellow-red dots are CD4, Foxp3 and CD8 positive cells.
[0133] Referring to Figures 14 and 15, the ratio of CD4 positive T cells to Foxp3 positive Treg cells was examined to confirm the immune activity in the tumor. As a result, in the aPD-1 and EB-AMDK39 EV co-administration group, the increase in Foxp3 positive regulatory T cells (Treg) was suppressed, and the CD4 / Treg ratio was confirmed to be significantly higher than in other treatment groups. In addition, the CD8 positive area was examined to investigate the expression of cytotoxic T cells. It was confirmed that these are also activated by CD4 T cells, and the CD8 positive area was significantly increased in the aPD-1 and EB-AMDK39EV co-administration group. The increase in CD8 in tumor tissue means that tumor cells are directly destroyed.
[0134] Example 8: Confirmation of anti-cancer effect of live Akkermansia muciniphila EB-AMDK39 bacteria or EV Figure 16 is a simplified diagram showing the in vivo experimental process to confirm the anticancer effect of single administration of Akkermansia muciniphila EB-AMDK39 live bacteria or EB-AMDK39 EV in a melanoma allograft mouse tumor model. After one week of acclimation, C57BL / 6 mice (female, 8 weeks old) were orally administered the antibiotics shown in Table 10 below for one week.
[0135] [Table 10]
[0136] 2×10 4 B16-F10 cells were subcutaneously injected into the thighs of mice together with 100 μL of Matrigel. From the sixth day after the transplantation of B16-F10 cells, when cancer cells began to appear, EB-AMDK39 was orally administered daily at 108 CFU / head / day, or EB-AMDK39 EV was intraperitoneally administered at 100 μg / head / alternate days three times a week. From the time the tumor was measured, the tumor size was measured using a caliper every two days, and the tumor size (volume) was calculated and shown in a graph in FIG. 17.
[0137] Referring to FIG. 17, it was confirmed that the tumor size was significantly smaller in the group orally administered with Akkermansia muciniphila EB-AMDK39 and the group intraperitoneally administered with EB-AMDK39 EV, compared to the control group allografted with B16-F10 cells. When comparing tumor sizes on day D22, the tumor size in the normal control group was 1064±140.3 mm. 3 In comparison, the Akkermansia muciniphila EB-AMDK39-treated group had a mean mean of 629 ± 148.1 mm 3 The mean tumor growth rate in the A. muciniphila EB-AMDK39 EV-treated group was 568±77.71 (P<0.05), showing a significant tumor growth inhibition effect of approximately 43%.
[0138] After the animal model experiment was completed, the mice were sacrificed on the 22nd, and the tumors were excised and weighed, as shown in FIG. 18. Also, the tumor cells were isolated and photographed, as shown in FIG. 19. The tumor weight in the normal control group was 2.423±0.2907g, while the tumor weights in the Akkermansia muciniphila EB-AMDK39 and EB-AMDK39 EV-administered groups were 1.564±0.1844g and 1.573±0.1517g, respectively, and both were confirmed to be significantly reduced (both P<0.05). As shown in FIG. 17, the tumor size was significantly reduced when Akkermansia muciniphila EB-AMDK39 strain or EB-AMDK39 EV was administered alone.
[0139] Example 9: Changes in immune cells in tumors following administration of live Akkermansia muciniphila EB-AMDK39 bacteria or EVs alone Immunohistochemical staining was performed to confirm changes in immune cell activity in tumor tissue following administration of Akkermansia muciniphila EB-AMDK39 strain or extracellular vesicles (EVs) derived from Akkermansia muciniphila EB-AMDK39 strain alone in a mouse allograft model using melanoma.
[0140] To confirm the activity of immune cells in the tumor tissue, immunohistochemical staining (IHC) analysis was performed for CD4, Foxp3, and CD8.
[0141] Immunohistochemical staining was performed on formalin-fixed / paraffin-embedded tissues using murine anti-CD4, anti-CD8, and anti-Foxp3 antibodies. Expression patterns were confirmed by microscopic examination, and analysis was performed using image analysis software Image J to measure DAB-positive areas (CD4, Foxp3, and CD8 positive cells) shown in reddish brown or reddish yellow. The positive areas in each micrograph were measured and compared, and the graph is shown in Figure 21.
[0142] 20 and 21, the ratio of CD4 positive T cells and Foxp3 positive Treg cells was examined to confirm the immune activity in the tumor. When Akkermansia muciniphila EB-AMDK39 strain or EB-AMDK39 EV was administered alone, the ratio of CD4 positive T cells and Foxp3 positive Treg cells was slightly increased compared to the control group, and CD8 positive T cells were examined to confirm cytotoxic T cells, and it was confirmed that EB-AMDK39-EV significantly increased the ratio. These results suggest that the Akkermansia muciniphila EB-AMDK39 strain-derived extracellular vesicles (EVs) according to the present invention contribute to the treatment of cancer by activating anti-cancer immunity through the increase in infiltration of CD8 positive T cells, which is a representative biomarker of the anti-cancer mechanism by immune anti-cancer drugs, into the tumor.
[0143] Example 10: Wound Healing Assay healing Confirmation of reduction in metastasis using the CT assay HT29 human colon cancer cells were cultured in McCoy's medium containing 10% FBS and 1% gentamicin at 5% CO2 and 37℃. HT29 colon cancer cells were dispensed into a 6-well cell culture plate and cultured to confluence. Then, a pipette tip was used to make a consistent scratch on the 6-well plate. Then, EB-AMDK39 EV was treated at 1μg / ml or 10μg / ml for 24 hours and observed under a microscope. The cell area was calculated using the Image J program.
[0144] To investigate the anti-cancer activity of EB-AMDK39 EVs, we performed a wound healing experiment. After wound formation in HT29 human colon cancer cells, Akkermansia sp.-derived extracellular vesicles (EVs) were treated at 1 μg / ml or 10 μg / ml for 24 hours to examine the degree of metastasis of the cancer cells.
[0145] 22a and 22b, in the wound healing experiment using HT29 cells, when Akkermansia sp.-derived extracellular vesicles (EVs) were administered at 1 μg / ml and 10 μg / ml, respectively, a 43.73% and 50.63% reduction in metastasis was observed, compared to the normal control group. In particular, a significant reduction was confirmed in the group treated with 10 μg / ml, with P<0.05.
[0146] Example 11: Evaluation of anti-inflammatory efficacy in HT29 cells Since cytokines and other immunomodulators are involved in regulating inflammatory responses in inflammatory bowel disease, we investigated whether the expression of these genes was affected by the administration of the strain of the present invention. For in vitro anti-inflammatory efficacy evaluation experiments, human-derived colon epithelial cells, HT-29 cells (ATCC HTB-38 TM The cells were cultured in McCoy's 5A modified medium (Gibco, USA) supplemented with 10% FBS (fetal bovine serum, Hyclone, USA) and 10 μg / ml gentamicin at 37°C in a 5% CO2 incubator (NUAIRE, USA). To confirm whether Akkermansia sp.-derived extracellular vesicles (EVs) suppress the expression of the IL-8 gene, a proinflammatory cytokine induced by LPS in HT-29 cells, real-time PCR was performed using the primers in Table 11 below.
[0147] Total RNA was extracted using TRIZOL Reagent (Sigma, USA), and cDNA was extracted from 1 μg of RNA using the M-mlV cDNA Synthesis Kit (Enzynomics, Korea). Real-time PCR was performed using the Quant Studio3 Real-time PCR System (Applied Biosystems, USA).
[0148] Gene expression of inflammatory cytokines was measured using SYBR Green TOPreal TM qPCR 2X PreMIX (Enzynomics, Korea) was used, and GAPDH was used as the internal standard. PCR conditions were 50°C for 4 min pre-incubation (for UDG), 95°C for 10 min, and 40 cycles of 95°C for 15 s and 60°C for 1 min. Data were analyzed by the delta CT method using the program built into QuantStudio Design & Analysis Software v1.4.3.
[0149] [Table 11]
[0150] As seen in Figure 23, when HT29 cells were treated with LPS alone at 100ng / ml for 6 hours, the expression of a representative inflammatory cytokine, IL-8, increased by about 3.7 times compared to the normal group (P<0.001). In contrast, in the group treated with LPS and the extracellular vesicles (EVs) derived from the Akkermansia sp. of the present invention at a concentration of 1μg / ml, the expression level of IL-8 was significantly decreased by 41% compared to the group treated with LPS alone (P<0.001).
[0151] The specific embodiments disclosed in this specification are for illustrating preferred embodiments of the present invention and should not be construed as limiting the present invention. The present invention can be implemented with various modifications and changes without departing from the spirit and scope of the present invention, and these facts will be obvious to those skilled in the art. The protection scope of the present invention should be defined by the appended claims, and it is intended that such various modifications and changes are included in the protection scope of the present invention.
[0152] [ka]
Claims
1. A pharmaceutical composition for preventing or treating cancer or an inflammatory disease, comprising extracellular vesicles (EVs) derived from Akkermansia sp. as an active ingredient.
2. The pharmaceutical composition for preventing or treating cancer or an inflammatory disease according to claim 1, wherein the Akkermansia strain is an Akkermansia muciniphila strain.
3. The pharmaceutical composition for preventing or treating cancer or an inflammatory disease according to claim 1, wherein the Akkermansia strain is Akkermansia muciniphila EB-AMDK39 strain (KCTC13765BP).
4. The pharmaceutical composition for preventing or treating cancer or an inflammatory disease according to claim 3, wherein the extracellular vesicles derived from the Akkermansia muciniphila EB-AMDK39 strain have an average diameter of 20 to 300 nm.
5. 2. The pharmaceutical composition for preventing or treating cancer or an inflammatory disease according to claim 1, wherein the cancer is any one selected from the group consisting of colorectal cancer, lung cancer, small cell lung cancer, gastric cancer, liver cancer, blood cancer, bone cancer, pancreatic cancer, skin cancer, head or neck cancer, skin or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, perianal cancer, colon cancer, breast cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, Hodgkin's disease, esophageal cancer, small intestine cancer, endocrine gland cancer, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, prostate cancer, chronic or acute leukemia, lymphocytic lymphoma, bladder cancer, kidney cancer, ureteral cancer, renal cell carcinoma, renal pelvic cancer, CNS tumor, primary CNS lymphoma, spinal cord tumor, brain stem glioma, and pituitary adenoma.
6. The pharmaceutical composition for preventing or treating cancer or inflammatory diseases according to claim 1, further comprising a cancer therapeutic agent selected from a chemical anticancer agent and an immune anticancer agent.
7. The pharmaceutical composition for preventing or treating cancer or an inflammatory disease according to claim 6, wherein the immunoanticancer agent is at least one selected from the group consisting of anti-PD1, anti-PDL1, anti-CTLA, anti-Tim3, and anti-LAG3.
8. The pharmaceutical composition for preventing or treating cancer or an inflammatory disease according to claim 1, further comprising Akkermansia sp.
9. The extracellular vesicles (EVs) derived from Akkermansia sp. and the chemical anticancer agent or immunological anticancer agent are administered simultaneously in one dosage form, or simultaneously or sequentially in separate dosage forms. The pharmaceutical composition for preventing or treating cancer or inflammatory diseases according to claim 6.
10. A health functional food for preventing or improving cancer, comprising extracellular vesicles (EV) derived from Akkermansia sp. as an active ingredient.
11. A veterinary composition for preventing or treating cancer or an inflammatory disease, comprising extracellular vesicles (EVs) derived from Akkermansia sp. as an active ingredient.
12. Akkermansia muciniphila EB-AMDK39 strain (KCTC13765BP).
Citation Information
Patent Citations
A composition for treating or preventing metabolic diseases, containing extracellular vesicles derived from Akkermansia muciniphila as an active ingredient
JP2017517569A
Image encoding / decoding method and apparatus using user-defined palette entry, and method for transmitting bitstream
WO2021060845A1
Anti-tumor composition
WO2021170137A1
